Pritelivir
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).
≈ 1 min read
Pritelivir. encyclopegia.org, snapshot enwiki-001359141062. /a/pritelivir
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.
US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020. In April 2026, the FDA granted priority review to the new drug application for pritelivir with target date for a final decision in late 2026.
See also
Amenamevir Adibelivir (IM-250)
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359141062 under CC BY-SA 4.0; modifications have been made.